Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer

Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with HR+/HER 2- advanced breast cancer.
Cancer
The randomized Phase III MONALEESA-2 trial showed a survival advantage of 63.9 months with front-line ribociclib, a CDK4/6 inhibitor, and the aromatase inhibitor letrozole, compared to 51.4 months with hormone therapy alone. The estimated six-year survival rate was 44.2% with ribociclib, compared with 32% for placebo. Gabriel Hortobagyi, M.D., professor of Breast Medical Oncology, presented the findings at the virtual European Society for Medical Oncology (ESMO) Congress 2021.
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated